Form 4: Vor Biopharma CEO Robert Ang Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Vor Biopharma's CEO, Robert Ang, disposed of 2,361 shares of common stock on May 6, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.
Summary
- On May 6, 2024, Robert Ang, the President and CEO of Vor Biopharma Inc., disposed of 2,361 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.
- The shares were sold at a price of $1.75 per share.
- Following the transaction, Robert Ang directly owns 810,368 shares of Vor Biopharma Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to insider trading. The sale of shares to cover tax obligations is a neutral event and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as officers and directors, trade their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a small percentage of the total outstanding shares and is related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/06/2024 | Date of transaction: Robert Ang disposed of 2,361 shares of common stock. |
| 05/07/2024 | Date of signature: Katie Kazem, Attorney-in-Fact, signed the Form 4 on behalf of Robert Ang. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.